Enzalutamide Data Presented at ASCO GU Symposium

[at noodls] – SAN FRANCISCO, CA and TOKYO — (Marketwire) — 02/13/13 — Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced that data for enzalutamide, an oral androgen receptor inhibitor, … more

View todays social media effects on MDVN

View the latest stocks trending across Twitter. Click to view dashboard

See who Medivation is hiring next, click here to view